
Intercept scores a mixed win on NASH Phase III sweepstakes, plans marketing pitch
Intercept Pharmaceuticals says they’ve cleared one of the high bars on their Phase III NASH study of obeticholic acid (OCA), setting up a pioneering marketing pitch in the coming months.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.